UPDATE: Cartesian Therapeutics (RNAC) - The Dilution Gap Just Closed
Non-dilutive K2HV debt buys the runway to AURORA topline — but the CMO is the third senior departure in seven months.
The single biggest hole I wrote about in the Cartesian deep dive was the dilution gap: a $120M cash pile, an ~$88M annualized burn, and an AURORA Phase 3 topline that wasn’t landing until late 2027 at the earliest. I called a pre-data raise the base case. Cartesian just routed around that by signing a venture debt facility with K2 HealthVentures for up to $150M, with $50M funded at close. Runway now extends into 2028 — comfortably past the newly-guided 1Q27 AURORA topline and the mid-2027 BLA filing. The setup I described as “right entry into a dilution-driven pullback” no longer requires the pullback.
The offsetting datapoint: CMO Miloš Miljković resigned the same day. That’s the third senior departure in seven months — CSO (Nov 2025), co-founder Kalayoglu off the board (March 2026), now CMO. Head of R&D Peter Traber stays through BLA.
The Receipts
The K2HV Facility (May 26, 2026). Senior secured term loans up to $150M, structured in four tranches: - First tranche: $50M, funded at closing (May 22, 2026) - Second tranche: $25M, available Jan 1 – Dec 1, 2027, contingent on positive AURORA Phase 3 data supportive of a BLA and $125M cumulative all-source financing (with at least $75M from a single equity raise) - Third tranche: $25M, available Jan 1 – Jun 1, 2028, contingent on FDA approval of Descartes-08 in gMG and first commercial sale - Fourth tranche: $50M, lender’s sole discretion
The Implication: The first two tranches are structured exactly the way you’d want them — the second tranche’s $75M equity-financing trigger means K2HV is contractually expecting Cartesian to raise equity after a positive Phase 3 readout, not before. That’s a clean sequencing.
Interest economics. Variable rate at the greater of 8.95% or Prime + 2.20%. Interest-only through July 1, 2029, then amortizing through the June 1, 2030 maturity. K2HV gets a conversion option on up to $15M of principal at $8.2526/share — about 28% above today’s $6.45 close. Capped at $5M conversion before the one-year anniversary.
Why it matters: The conversion strike is set above market, so this isn’t toxic financing. The 8.95% floor is expensive money — call it ~$4.5M/year of interest on the funded $50M — but cheap relative to selling stock at $6.45.
Runway math. Cash was $120.4M at March 31, 2026. Add the $50M first tranche, less ~$2M in financing fees and an end-of-term fee accrual, you’re at roughly $168M pro forma. Against the $22.1M Q1 burn ($88M annualized), that’s ~19 months of cash — putting runway squarely into early 2028, comfortably past the 1Q27 topline and the mid-2027 BLA filing they’re now guiding to.
The Catalyst Calendar moved forward. Phase 3 AURORA topline is now guided to 1Q27 (previously informally late 2027/1H 2028 in my own modeling). HELIOS pediatric data moved to 1H27 (was 4Q26 in the deck — they pushed it out a quarter). TRITON myositis interim still 1H27.
The Implication: The 1Q27 AURORA guide is the more aggressive datapoint. A pivotal trial that opened in May 2025 with ~100 patients and a Month 4 primary endpoint reading out by March 2027 implies enrollment was effectively complete by November 2026. Either enrollment is going faster than I modeled, or management is telegraphing confidence in the operational tape. Either way, the time-to-binary just compressed.
The CMO Exit. Miloš Miljković, CMO since March 2024, resigned May 22 “for personal reasons to return to practicing medicine.” Six months of severance, pro-rated bonus, COBRA. Peter Traber (Head of R&D, ex-Selecta CMO, ex-Galectin CEO, ex-GSK CMO) stays through BLA submission.
Why it matters: This is the third senior departure in seven months — CSO (November 2025), co-founder Kalayoglu off the board (March 2026, 19.9% stake intact), now CMO. Individually each has a benign explanation. Cumulatively, it’s a pattern I have to flag. The mitigant: Traber is arguably more credentialed than Miljković for the BLA submission phase, and he’s the one staying.
The Scientific Reality Check
Nothing in the underlying clinical thesis changed today. The Phase 2b data I dissected in the deep dive — 7.1-point MG-ADL reduction at Month 12 in biologic-naïve patients (n=7), 4.8-point reduction in the full primary efficacy dataset (n=12), no CRS, no ICANS, no lymphodepletion — is exactly the same hand AURORA is being dealt. What changed is the financing window around that hand.
The thesis I laid out had two real risks: (1) AURORA fails or underwhelms at the prespecified Month 4 primary endpoint, where the Phase 2b delta was a moderate 3.4 points vs. placebo with p=0.0409 in an n=19 subgroup; and (2) Cartesian gets forced into a depressed pre-data secondary that destroys the asymmetry. Today’s news doesn’t touch (1) — the small-n, post-hoc subgroup risk is what it is. But (2) is materially de-risked.
The K2HV deal also embeds a useful third-party validation signal. K2HV is a credentialed life-sci debt shop (Kymera, Cogent, others); they did diligence on AURORA, the manufacturing facility, and the BLA path before writing the check. Their underwriting standard isn’t a green light on the science, but it’s not nothing.
